Luis Flores
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Flores has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abigail De Avila
CEVAXIN, Panama, Panama, Panama
2 shared publications - Ana Lucas Quintero
Pediatrics Clinic , Panama, Panama, Panama
2 shared publications - Cynthia Gadea
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Emmanuel Guillén
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Isaac Fernández Camargo
Faculty of Medicine, University of Panama, Panama City, Panama, Panama
2 shared publications - Jaime Ricardo Sevillano Giraldez
Department of Population Intelligence, Endpoints Research Sites Network, Panama, Panama, Panama
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by MDPI AG in Preprints.org
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025
Background/Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We characterized self-reported maternal and neonatal events and outcomes to generate early post-introduction real-world safety evidence from Central America. Methods. This retrospective descriptive observational study included women aged 18 years or older vaccinated with RSVpreF between 32.0 and 36.6 weeks of gestation from July through December 2025 and recruited from January through July 2026. Structured telephone, virtual, or in-person interviews were used. We calculated absolute and relative frequencies and 95% Wilson confidence intervals (CIs). Results. Of 225 questionnaires obtained, 200 were eligible for analysis. Mean maternal age was 28.1 years (SD 6.4). At least one reaction was reported by 55.5% of participants, mainly local; injection-site pain was most frequent (48.0%). At least one obstetric condition was reported by 17.5%, including hypertensive disorders of pregnancy (12.0%). Preterm birth occurred in 2.0% and low birth weight in 2.5%. No fetal or neonatal deaths, thrombocytopenia, paralysis, facial paralysis, or Guillain–Barré syndrome were reported. Jaundice was the most frequent neonatal morbidity (20.0%). Conclusions. In this cohort, self-reported reactogenicity was mainly local, and no unexpected cluster of events was apparent. Participant selection, retrospective self-report, absence of an unvaccinated comparator, and sample size limit risk estimation and detection of uncommon events. The findings provide early active-pharmacovigilance evidence from Central America and support continued surveillance with clinically verified maternal and neonatal outcomes.
- 17 August 2026
- Published by MDPI AG in Preprints.org
Open AccessSafety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025
Background/Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We characterized self-reported maternal and neonatal events and outcomes to generate early post-introduction real-world safety evidence from Central America. Methods. This retrospective descriptive observational study included women aged 18 years or older vaccinated with RSVpreF between 32.0 and 36.6 weeks of gestation from July through December 2025 and recruited from January through July 2026. Structured telephone, virtual, or in-person interviews were used. We calculated absolute and relative frequencies and 95% Wilson confidence intervals (CIs). Results. Of 225 questionnaires obtained, 200 were eligible for analysis. Mean maternal age was 28.1 years (SD 6.4). At least one reaction was reported by 55.5% of participants, mainly local; injection-site pain was most frequent (48.0%). At least one obstetric condition was reported by 17.5%, including hypertensive disorders of pregnancy (12.0%). Preterm birth occurred in 2.0% and low birth weight in 2.5%. No fetal or neonatal deaths, thrombocytopenia, paralysis, facial paralysis, or Guillain–Barré syndrome were reported. Jaundice was the most frequent neonatal morbidity (20.0%). Conclusions. In this cohort, self-reported reactogenicity was mainly local, and no unexpected cluster of events was apparent. Participant selection, retrospective self-report, absence of an unvaccinated comparator, and sample size limit risk estimation and detection of uncommon events. The findings provide early active-pharmacovigilance evidence from Central America and support continued surveillance with clinically verified maternal and neonatal outcomes.
- Open Access
- 14 August 2026
- Published by MDPI AG in Preprints.org
Maternal Vaccination Perceptions, Attitudes and Practices Among Urban Women Receiving Antenatal Care in Panama City: A Cross-Sectional Study
Background/Objectives: Maternal immunization is a public health priority within Panama's Expanded Programme on Immunization (EPI), yet coverage among pregnant women remains below target and little local evidence is available on perceptions and practices among women engaged in antenatal care. We aimed to describe vaccination-related perceptions, attitudes and practices in an urban, predominantly private-care sample and to explore factors associated with acceptance. Methods: We conducted a cross-sectional study in 204 pregnant women aged ≥18 years, recruited by convenience sampling and surveyed with an anonymous, self-administered questionnaire. Vaccine acceptance was defined as having received or intending to receive at least one recommended vaccine during the current pregnancy. Participant characteristics were summarized descriptively; bivariate analyses and multivariable Poisson regression with robust variance estimated adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: Acceptance was 93.1% (190/204). Most participants had higher education (88.2%) and private antenatal care (77.9%); all reported antenatal care. Healthcare professionals were the main information source (92.6%) and most trusted source (98.0%). A vaccination recommendation was reported by 84.3% of participants; 96.5% of reported recommendations came from healthcare professionals. Influenza was most frequently received (56.9%), RSV most frequently planned (51.5%), and COVID-19 most frequently refused (47.1%). Recommendation was associated with acceptance (adjusted PR 1.22; 95% CI 1.02–1.45; p = 0.029), but may reflect broader access to high-quality care. Conclusions: In this selected urban sample, acceptance was high among women engaged in antenatal care. The findings cannot characterize national acceptance; improving coverage likely requires equitable access to antenatal care, evidence-based counseling, recommendations, and vaccination opportunities.
- 14 August 2026
- Published by MDPI AG in Preprints.org
Open AccessMaternal Vaccination Perceptions, Attitudes and Practices Among Urban Women Receiving Antenatal Care in Panama City: A Cross-Sectional Study
Background/Objectives: Maternal immunization is a public health priority within Panama's Expanded Programme on Immunization (EPI), yet coverage among pregnant women remains below target and little local evidence is available on perceptions and practices among women engaged in antenatal care. We aimed to describe vaccination-related perceptions, attitudes and practices in an urban, predominantly private-care sample and to explore factors associated with acceptance. Methods: We conducted a cross-sectional study in 204 pregnant women aged ≥18 years, recruited by convenience sampling and surveyed with an anonymous, self-administered questionnaire. Vaccine acceptance was defined as having received or intending to receive at least one recommended vaccine during the current pregnancy. Participant characteristics were summarized descriptively; bivariate analyses and multivariable Poisson regression with robust variance estimated adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: Acceptance was 93.1% (190/204). Most participants had higher education (88.2%) and private antenatal care (77.9%); all reported antenatal care. Healthcare professionals were the main information source (92.6%) and most trusted source (98.0%). A vaccination recommendation was reported by 84.3% of participants; 96.5% of reported recommendations came from healthcare professionals. Influenza was most frequently received (56.9%), RSV most frequently planned (51.5%), and COVID-19 most frequently refused (47.1%). Recommendation was associated with acceptance (adjusted PR 1.22; 95% CI 1.02–1.45; p = 0.029), but may reflect broader access to high-quality care. Conclusions: In this selected urban sample, acceptance was high among women engaged in antenatal care. The findings cannot characterize national acceptance; improving coverage likely requires equitable access to antenatal care, evidence-based counseling, recommendations, and vaccination opportunities.